Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis Panel, Therapy of CML.
Date: June 16-18, 2003.
Time: 7 p.m. to 11 a.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Houston Plaza, 6633 Travis Street, Houston, TX 77030.
Contact Person: Claudio A. Dansky Ullmann, MD, Scientific Review Administrator, National Cancer Institute, Division of Extramural Activities, Grants Review Branch, Research Programs Review Branch, 6116 Executive Blvd., Rm 8119, MSC 8328, Bethesda, MD 20892, 301-451-4761, firstname.lastname@example.org.Start Signature
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93,396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Dated: May 8, 2003.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 03-12093 Filed 5-14-03; 8:45 am]
BILLING CODE 4140-01-M